{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:45:26Z","timestamp":1793724326804,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.msard.2026.107090","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T06:45:22Z","timestamp":1771742722000},"page":"107090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Psychometric validation of PROMIS-Fatigue-MS-8a and MSIS-29v2 questionnaires in relapsing multiple sclerosis participants enrolled in a phase 2 trial of frexalimab"],"prefix":"10.1016","volume":"109","author":[{"given":"Patrick","family":"Vermersch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lita","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Gourlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Hakimi-Hawken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Saubadu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Truffinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Arnould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-5855","authenticated-orcid":false,"given":"Jerome","family":"Msihid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107090_bib0001","article-title":"Analysis of the psychometric properties of the multiple sclerosis impact scale-29 (MSIS-29) in relapsing-remitting multiple sclerosis using classical and modern test theory","volume":"2","author":"Bacci","year":"2016","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2026.107090_bib0002","series-title":"Eprovide By MAPI Research Trust","year":"2025"},{"issue":"1","key":"10.1016\/j.msard.2026.107090_bib0003","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1038\/s41598-020-61076-1","article-title":"Fatigue profiles in patients with multiple sclerosis are based on severity of fatigue and not on dimensions of fatigue","volume":"10","author":"Beckerman","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.msard.2026.107090_bib0004","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/1756285616671882","article-title":"Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon \u03b2-1a: an observational study SKORE","volume":"10","author":"Bene\u0161ov\u00e1","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"8","key":"10.1016\/j.msard.2026.107090_bib0005","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/sleep\/33.8.1061","article-title":"Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment","volume":"33","author":"Braley","year":"2010","journal-title":"Sleep."},{"issue":"12","key":"10.1016\/j.msard.2026.107090_bib0006","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16526","article-title":"Treating to target in multiple sclerosis: do we know how to measure whether we hit it?","volume":"31","author":"Bsteh","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2026.107090_bib0007","unstructured":"Cohen J., 1988. Statistical Power Analysis For the Behavioral Sciences, 2nd Edition ed., New York."},{"issue":"10","key":"10.1016\/j.msard.2026.107090_bib0008","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41582-024-01006-1","article-title":"Assessing disease progression and treatment response in progressive multiple sclerosis","volume":"20","author":"Comi","year":"2024","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.107090_bib0009","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s11136-011-0011-8","article-title":"A PROMIS fatigue short form for use by individuals who have multiple sclerosis","volume":"21","author":"Cook","year":"2012","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.msard.2026.107090_bib0010","series-title":"The Patient Reported Outcome Consortium","year":"2024"},{"issue":"6","key":"10.1016\/j.msard.2026.107090_bib0011","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s11136-011-0009-2","article-title":"Self-report fatigue questionnaires in multiple sclerosis, parkinson's disease and stroke: a systematic review of measurement properties","volume":"21","author":"Elbers","year":"2012","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.msard.2026.107090_bib0012","unstructured":"Guidance for using PROMIS measures with people with multiple sclerosis. HealthMeasures; 2024. https:\/\/www.healthmeasures.net\/images\/applications\/Guidance_for_Using_PROMIS_Measures_with_People_with_Multiple_Sclerosis_17Sept2024.pdf. (Accessed 15 April 2025)."},{"issue":"Pt 5","key":"10.1016\/j.msard.2026.107090_bib0013","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/brain\/124.5.962","article-title":"The multiple sclerosis impact scale (MSIS-29): A new patient-based outcome measure","volume":"124","author":"Hobart","year":"2001","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.msard.2026.107090_bib0014","first-page":"1","article-title":"Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods","volume":"13","author":"Hobart","year":"2009","journal-title":"Health Technol. Assess. (Rockv)"},{"key":"10.1016\/j.msard.2026.107090_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103117","article-title":"Standardizing fatigue measurement in multiple sclerosis: the validity, responsiveness and score interpretation of the PROMIS SF v1.0 - fatigue (MS) 8a","volume":"54","author":"Kamudoni","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107090_bib0016","article-title":"The quality of life in patients with multiple sclerosis - association with depressive symptoms and physical disability: a prospective and observational study","volume":"13","author":"Ko\u0142tuniuk","year":"2022","journal-title":"Front. Psychol."},{"issue":"2","key":"10.1016\/j.msard.2026.107090_bib0017","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","article-title":"A guideline of selecting and reporting intraclass correlation coefficients for reliability research","volume":"15","author":"Koo","year":"2016","journal-title":"J. Chiropr. Med."},{"issue":"2","key":"10.1016\/j.msard.2026.107090_bib0018","first-page":"266","article-title":"The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure","volume":"75","author":"McGuigan","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.msard.2026.107090_bib0019","series-title":"MS Atlas","year":"2023"},{"key":"10.1016\/j.msard.2026.107090_bib0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12874-016-0167-6","article-title":"Minimal important differences for fatigue patient reported outcome measures-a systematic review","volume":"16","author":"Nordin","year":"2016","journal-title":"BMC. Med. Res. Methodol."},{"issue":"1","key":"10.1016\/j.msard.2026.107090_bib0021","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/s12883-021-02396-1","article-title":"Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review","volume":"21","author":"Oliva Ramirez","year":"2021","journal-title":"BMC. Neurol."},{"key":"10.1016\/j.msard.2026.107090_bib0022","series-title":"Health Measures","year":"2024"},{"issue":"1","key":"10.1016\/j.msard.2026.107090_bib0023","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s41687-023-00612-9","article-title":"Experience and measurement of fatigue in adults with crohn's disease: results from qualitative interviews and a longitudinal 2-week daily diary pilot study","volume":"7","author":"Regueiro","year":"2023","journal-title":"J. Patient Report. Outcomes"},{"issue":"6","key":"10.1016\/j.msard.2026.107090_bib0024","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/jnnp.73.6.701","article-title":"Multiple sclerosis impact scale (MSIS-29): reliability and validity in hospital based samples","volume":"73","author":"Rizi","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.msard.2026.107090_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106169","article-title":"Psychometric properties of patient-reported outcome measures, measuring fatigue in patients with multiple sclerosis, a systematic review","volume":"92","author":"Ruzzi","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2026.107090_bib0026","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/j.1541-0420.2008.01082_11.x","article-title":"Quality of life: the assessment, analysis, and interpretation of patient-reported outcomes by fayers","volume":"64","author":"Sloan","year":"2008","journal-title":"P. M. and Machin, D. Biometrics"},{"issue":"10","key":"10.1016\/j.msard.2026.107090_bib0027","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1177\/13524585221105465","article-title":"The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials","volume":"28","author":"Strijbis","year":"2022","journal-title":"Multiple Sclerosis"},{"issue":"3","key":"10.1016\/j.msard.2026.107090_bib0028","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jpsychires.2011.12.001","article-title":"Development of a clinical global impression scale for fatigue","volume":"46","author":"Targum","year":"2012","journal-title":"J. Psychiatr. Res."},{"issue":"7","key":"10.1016\/j.msard.2026.107090_bib0029","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2309439","article-title":"Inhibition of CD40L with frexalimab in multiple sclerosis","volume":"390","author":"Vermersch","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.msard.2026.107090_bib0030","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1177\/13524585241288393","article-title":"Physical and psychological aspects of multiple sclerosis: revisiting the multiple sclerosis impact scale (MSIS-29)","volume":"30","author":"Young","year":"2024","journal-title":"Multiple Sclerosis"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:23:11Z","timestamp":1781526191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826001264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":30,"alternative-id":["S2211034826001264"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107090","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychometric validation of PROMIS-Fatigue-MS-8a and MSIS-29v2 questionnaires in relapsing multiple sclerosis participants enrolled in a phase 2 trial of frexalimab","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107090"}}